Physician profile
Benjamin K Yang
NPI 1235356999
$6,595.96
in general payments reported to CMS, 2019-2025
30 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $412 · 2021: $538 · 2022: $871 · 2023: $522 · 2024: $3,794 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718 · Education: $1,686 · Travel and Lodging: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.72 |
| Education | $1,685.99 |
| Travel and Lodging | $1,132.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,584.12 | 2020-2024 | |
| Procept Biorobotics Corporation | $1,181.71 | 2022-2024 | Aquabeam System |
| Teleflex LLC | $776.17 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $484.01 | 2019-2024 | Spaceoar System |
| Astellas Pharma US INC | $410.94 | 2019-2024 | Xtandi, Veozah, Myrbetriq |
| Janssen Biotech, INC. | $388.73 | 2021-2024 | Erleada, Akeega, Balversa |
| Endo Pharmaceuticals INC. | $210.79 | 2019-2023 | Xiaflex |
| Caldera Medical, INC | $159.49 | 2022-2023 | Desara |
| Coloplast Corp | $150.26 | 2020-2025 | |
| Verity Pharmaceuticals INC. | $141.41 | 2023-2024 | Trelstar |
| Sumitomo Pharma America, INC. | $135.64 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $123.97 | 2021-2022 | |
| Abbvie INC. | $117.90 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.38 | 2021-2022 | |
| Axonics, INC. | $81.04 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $75.16 | 2020-2021 | |
| Pfizer INC. | $65.04 | 2019-2022 | |
| Neotract INC. | $57.79 | 2019 | |
| Immunitybio, INC. | $55.88 | 2024-2025 | |
| Allergan, INC. | $54.47 | 2020-2021 | |
| Urovant Sciences INC | $49.70 | 2021-2022 | |
| Hollister Incorporated | $38.21 | 2022 | |
| Acerus Pharmaceuticals Corporation | $36.08 | 2020-2022 | |
| Urogen Pharma, INC. | $34.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $34.39 | 2022 | |
| Telix Pharmaceuticals | $19.92 | 2023 | Illuccix |
| Astrazeneca Pharmaceuticals Lp | $16.05 | 2019 | |
| 180 Medical, INC. | $15.83 | 2020 | |
| Edap Technomed INC | $15.44 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.